Other: MSCs ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica1

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,342 Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04749667
(ClinicalTrials.gov)
August 9, 202120/1/2021Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple SclerosisStudy of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple SclerosisMultiple Sclerosis;Progressive Multiple SclerosisOther: MSCs;Drug: SalineHaukeland University HospitalUniversity of Bergen;University Hospital Ulm;University Hospital, Akershus;St. Olavs Hospital;University Hospital of North NorwayRecruiting18 Years55 YearsAll18Phase 1/Phase 2Norway